Protara Therapeutics, Inc. (TARA)
Nasdaq: TARA · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2006
Who owns Protara Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
JANUS HENDERSON GROUP Ltd. holds 8.4% of Common Stock, as its SCHEDULE 13G/A filed Aug 13, 2026 says.
Directors and officers
14
report now, of 47 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 9.6% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Apr 27, 2026 · Common Stock · 4.7% in Jan 21, 2026
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 7, 2026 · Common Stock, par value $0.001 per share · 5.1% in Mar 2, 2026
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 9.9% in Feb 14, 2025
Opaleye Management, Inc.
SCHEDULE 13G/A · filed Apr 28, 2025 · Common Stock · reported falling below 5%, from 5.32% in Feb 14, 2025
Kenneth Griffin
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.001 par value per share (the "Shares") · reported falling below 5%
Woodline Partners LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed May 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.56% in Feb 12, 2025
What TARA reports owning in othersstakes of 5% or more, and other ties
5 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 10, 2026.
Insider tradesForm 4
3sales
0purchases
0sales on a scheduled plan
2people selling
$1.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 53 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Shefferman Jesse | CEO and President | 1 | $900,000 | 0 | 0 | $0 |
| Zummo Jacqueline | Chief R&D Officer | 2 | $100,000 | 0 | 0 | $0 |